Form 4: Amicus Therapeutics CEO Sells Shares Under 10b5-1 Plan

Amicus Therapeutics CEO Bradley L. Campbell executed a pre-planned sale of 14,587 common shares after exercising stock options.

Summary

• Bradley L. Campbell, President and CEO, and Director of Amicus Therapeutics, Inc. (FOLD), reported transactions on December 1, 2025.
• Campbell exercised options to acquire 14,587 shares of common stock at an exercise price of $9.03 per share.
• Concurrently, Campbell sold 14,587 shares of common stock at a weighted average price of $10.0097 per share, with individual transaction prices ranging from $10.00 to $10.04.
• These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 13, 2024.
• Following these reported transactions, Campbell directly beneficially owns 1,137,282 shares of common stock and 70,426 stock options.

Sentiment

Score: 5

Explanation: The filing reports a routine, pre-planned insider transaction (exercise and sale) under a 10b5-1 plan, which is generally considered neutral as it does not reflect new discretionary trading based on recent material non-public information. The profit from the exercise and sale is a positive for the insider but not necessarily for the company's immediate outlook.

Positives

• The sale price of $10.0097 per share is higher than the exercise price of $9.03 per share, indicating a profit for the insider on these specific shares.

Negatives

• The sale of shares by an insider, even if pre-planned, can sometimes be perceived negatively by the market, though the Rule 10b5-1 plan mitigates this.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This is a routine insider transaction filing (Form 4) and does not provide specific industry context or relate to broader industry trends beyond the general practice of executives managing their equity compensation.

Stakeholder Impact

• Shareholders: A routine insider sale under a 10b5-1 plan is generally not considered a significant signal of management's confidence or lack thereof, as it is pre-scheduled. The volume of shares sold is a small fraction of the total outstanding shares.

Key Dates

Keywords

Amicus Therapeutics, FOLD, Insider Trading, Form 4, Stock Options, Rule 10b5-1, CEO, Share Sale